Drug Profile
PF 06730512
Alternative Names: PF-06730512Latest Information Update: 06 Feb 2024
Price :
$50
*
At a glance
- Originator Pfizer
- Class Immunoglobulin Fc fragments; Recombinant fusion proteins; Urologics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Focal segmental glomerulosclerosis
Most Recent Events
- 31 Oct 2023 Discontinued - Phase-I for Focal segmental glomerulosclerosis (In volunteers) in Belgium (IV) prior to October 2023
- 31 Oct 2023 Discontinued - Phase-I for Focal segmental glomerulosclerosis (In volunteers) in Belgium (SC) prior to October 2023
- 31 Oct 2023 Discontinued - Phase-II for Focal segmental glomerulosclerosis in United Kingdom, Czech Republic, Canada, France, Germany, Italy, Japan, Mexico, Poland, Slovakia, Spain, USA (IV) prior to October 2023